{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:25:34Z","timestamp":1790825134414,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"\"Thousand Talents Plan\" project of Jiangxi Province","award":["JXSQ2023201030"],"award-info":[{"award-number":["JXSQ2023201030"]}]},{"name":"Kidney Disease Engineering Technology Research Centre Foundation of Jiangxi Province","award":["No. 20164BCD40095"],"award-info":[{"award-number":["No. 20164BCD40095"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82260143"],"award-info":[{"award-number":["No. 82260143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Science and Technology Plan of Health Commission of Jiangxi Province","award":["SJKP220210087"],"award-info":[{"award-number":["SJKP220210087"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-024-01461-6","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T12:02:10Z","timestamp":1725883330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The efficacy of rituximab in the treatment of IgA vasculitis nephritis"],"prefix":"10.1007","volume":"24","author":[{"given":"Yi","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"issue":"7","key":"1461_CR1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11926-021-01013-x","volume":"23","author":"K Yaseen","year":"2021","unstructured":"Yaseen K, Herlitz LC, Villa-Forte A. IgA vasculitis in adults: a rare yet challenging disease. Curr Rheumatol Rep. 2021;23(7):50.","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"1461_CR2","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.3390\/jcm10112310","volume":"10","author":"E Pillebout","year":"2021","unstructured":"Pillebout E. IgA vasculitis and IgA nephropathy: same disease? J Clin Med. 2021;10(11):2310.","journal-title":"J Clin Med"},{"issue":"3","key":"1461_CR3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1523-1755.2001.059003823.x","volume":"59","author":"JC Davin","year":"2001","unstructured":"Davin JC, Ten Berge IJ, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schonlein purpura nephritis? Kidney Int. 2001;59(3):823\u201334.","journal-title":"Kidney Int"},{"issue":"188","key":"1461_CR4","first-page":"495","volume":"47","author":"Y Nakamoto","year":"1978","unstructured":"Nakamoto Y, Asano Y, Dohi K, et al. Primary IgA glomerulonephritis and Schonlein-Henoch purpura nephritis: Clinicopathological and immunohistological characteristics. Q J Med. 1978;47(188):495\u2013516.","journal-title":"Q J Med"},{"issue":"9","key":"1461_CR5","first-page":"1579","volume":"33","author":"L Berthelot","year":"2018","unstructured":"Berthelot L, Jamin A, Viglietti D, et al. Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. Nephrol Dial Transplant. 2018;33(9):1579\u201390.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"1461_CR6","doi-asserted-by":"crossref","first-page":"e0188718","DOI":"10.1371\/journal.pone.0188718","volume":"12","author":"E Pillebout","year":"2017","unstructured":"Pillebout E, Jamin A, Ayari H, et al. Biomarkers of IgA vasculitis nephritis in children. PLoS ONE. 2017;12(11):e0188718.","journal-title":"PLoS ONE"},{"issue":"2","key":"1461_CR7","first-page":"005128","volume":"2","author":"D Hahn","year":"2023","unstructured":"Hahn D, Hodson EM, Craig JC. Interventions for preventing and treating kidney disease in IgA vasculitis. Cochrane Database Syst Rev. 2023;2(2):005128.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"1461_CR8","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Foa R, et al. Rituximab in B-cell Hematologic Malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232\u201373.","journal-title":"Adv Ther"},{"issue":"8","key":"1461_CR9","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.autrev.2012.09.002","volume":"12","author":"AG Kattah","year":"2013","unstructured":"Kattah AG, Fervenza FC, Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev. 2013;12(8):854\u20139.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"1461_CR10","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28(4):1306\u201313.","journal-title":"J Am Soc Nephrol"},{"key":"1461_CR11","doi-asserted-by":"crossref","unstructured":"Cancarevic I, Malik BH. Use of rituximab in management of rapidly progressive glomerulonephritis. Cureus 2020.","DOI":"10.7759\/cureus.6820"},{"issue":"4","key":"1461_CR12","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102490","volume":"19","author":"J Hernandez-Rodriguez","year":"2020","unstructured":"Hernandez-Rodriguez J, Carbonell C, Miron-Canelo JA, et al. Rituximab treatment for IgA vasculitis: a systematic review. Autoimmun Rev. 2020;19(4): 102490.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1461_CR13","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2009.116657","volume":"69","author":"S Ozen","year":"2010","unstructured":"Ozen S, Pistorio A, Iusan SM, et al. EULAR\/PRINTO\/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008 Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798\u2013806.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1461_CR14","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/art.1780330809","volume":"33","author":"JA Mills","year":"1990","unstructured":"Mills JA, Michel BA, Bloch DA, et al. The American college of rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum. 1990;33(8):1114\u201321.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1461_CR15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jama.2015.0602","volume":"313","author":"AS Levey","year":"2015","unstructured":"Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015;313(8):837\u201346.","journal-title":"JAMA"},{"issue":"9","key":"1461_CR16","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00296-022-05153-w","volume":"42","author":"C Valero","year":"2022","unstructured":"Valero C, Baldivieso-Ach\u00e1 JP, Uriarte M, et al. Vasculitis flare after COVID-19: report of two cases in patients with preexistent controlled IgA vasculitis and review of the literature. Rheumatol Int. 2022;42(9):1643\u201352.","journal-title":"Rheumatol Int"},{"key":"1461_CR17","unstructured":"Patel K, Kariya P, Makwana P. Henoch-Schoenle in purpura with IgA nephropathy treated with rituximab: a case report. 2022."},{"issue":"3","key":"1461_CR18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3899\/jrheum.200358","volume":"48","author":"ML Riley","year":"2021","unstructured":"Riley ML, Maheshwari A, Peredo-Wende R. Late-onset hemorrhagic cutaneous immunoglobulin a vasculitis. J Rheumatol. 2021;48(3):463\u20134.","journal-title":"J Rheumatol"},{"key":"1461_CR19","doi-asserted-by":"crossref","first-page":"101100","DOI":"10.1016\/j.ajoc.2021.101100","volume":"22","author":"I Hernanz","year":"2021","unstructured":"Hernanz I, Larque AB, Quintana LF, et al. Scleritis and sclerokeratitis associated with IgA vasculitis: a case series. Am J Ophthalmol Case Rep. 2021;22:101100.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"1461_CR20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4103\/AJIM.AJIM_6_20","volume":"9","author":"M Amarapur","year":"2021","unstructured":"Amarapur M, Biradar S. Adult-onset immunoglobulin A vasculitis. APIK J Intern Med. 2021;9(2):120\u20132.","journal-title":"APIK J Intern Med"},{"issue":"11","key":"1461_CR21","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.ekir.2020.08.012","volume":"5","author":"NN Uppal","year":"2020","unstructured":"Uppal NN, Kello N, Shah HH, et al. De Novo ANCA-associated vasculitis with glomerulonephritis in COVID-19. Kidney Int Rep. 2020;5(11):2079\u201383.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"1461_CR22","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.ekir.2020.08.016","volume":"5","author":"AS Suso","year":"2020","unstructured":"Suso AS, Mon C, O\u00f1ate Alonso I, et al. IgA vasculitis with nephritis (Henoch-Sch\u00f6nlein Purpura) in a COVID-19 patient. Kidney Intern Rep. 2020;5(11):2074\u20138.","journal-title":"Kidney Intern Rep"},{"key":"1461_CR23","doi-asserted-by":"crossref","unstructured":"Mamlouk O, Lin JS, Abdelrahim M, et al. Checkpoint inhibitor-related renal vasculitis and use of rituximab. Journal for Immunotherapy of Cancer 2020; 8 (2).","DOI":"10.1136\/jitc-2020-000750"},{"key":"1461_CR24","first-page":"8863858","volume":"2020","author":"A Al Harash","year":"2020","unstructured":"Al Harash A, Saeli S, Lucke M, et al. IgA vasculitis nephritis: a case series and comparison of treatment guidelines. Case Rep Rheumatol. 2020;2020:8863858.","journal-title":"Case Rep Rheumatol"},{"issue":"6","key":"1461_CR25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.22270\/jddt.v9i6-s.3744","volume":"9","author":"K El-Reshaid","year":"2019","unstructured":"El-Reshaid K, Al-Bader S. The limited role and risky profile of Rituximab in nephritis associated with Henoch-Sch\u00f6nlein purpura. J Drug Deliv Ther. 2019;9(6):12\u20135.","journal-title":"J Drug Deliv Ther"},{"issue":"7","key":"1461_CR26","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/imj.13948","volume":"48","author":"M Torosoff","year":"2018","unstructured":"Torosoff M, Breen T, Balulad S, et al. Resolution of sinus bradycardia, high-grade heart block, and left ventricular systolic dysfunction with rituximab therapy in Henoch-Schonlein purpura. Intern Med J. 2018;48(7):868\u201371.","journal-title":"Intern Med J"},{"key":"1461_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-018-0285-2","volume":"16","author":"CB Crayne","year":"2018","unstructured":"Crayne CB, Eloseily E, Mannion ML, et al. Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol. 2018;16:1\u20136.","journal-title":"Pediatr Rheumatol"},{"issue":"2","key":"1461_CR28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2016.12.691","volume":"139","author":"C-Y Yeh","year":"2017","unstructured":"Yeh C-Y, Davis CM. Long-lasting remission of severe refractory Henoch-Schonlein purpura nephritis with rituximab. J Allergy Clin Immunol. 2017;139(2):213\u2013213.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1461_CR29","first-page":"20","volume":"10","author":"S Lundberg","year":"2017","unstructured":"Lundberg S, Westergren E, Smolander J, et al. B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. Clin Kidney J. 2017;10(1):20\u20136.","journal-title":"Clin Kidney J"},{"issue":"11","key":"1461_CR30","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/rheumatology\/kew286","volume":"55","author":"E Van de Perre","year":"2016","unstructured":"Van de Perre E, Smith RM, Bardsley V, et al. Successful outcome using bortezomib in adult refractory IgA vasculitis: a case report. Rheumatology. 2016;55(11):2089\u201391.","journal-title":"Rheumatology"},{"key":"1461_CR31","first-page":"503A","volume":"27","author":"R Fenoglio","year":"2016","unstructured":"Fenoglio R, Roccatello D. Successfull rituximab treatment for adult patients with severe IgA Vasculitis-Henoch-Schoenlein purpura nephritis (HSPN). J Am Soc Nephrol. 2016;27:503A.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1461_CR32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/03009742.2015.1058417","volume":"45","author":"M Bellan","year":"2016","unstructured":"Bellan M, Pirisi M, Sainaghi PP. Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Scholein purpura with rituximab. Scand J Rheumatol. 2016;45(1):83\u20134.","journal-title":"Scand J Rheumatol"},{"key":"1461_CR33","first-page":"269895","volume":"2015","author":"P Hamilton","year":"2015","unstructured":"Hamilton P, Ogundare O, Raza A, et al. Long-term therapeutic plasma exchange to prevent end-stage kidney disease in adult severe resistant Henoch-Schonlein purpura nephritis. Case Rep Nephrol. 2015;2015:269895\u2013269895.","journal-title":"Case Rep Nephrol"},{"key":"1461_CR34","doi-asserted-by":"crossref","first-page":"619218","DOI":"10.1155\/2014\/619218","volume":"2014","author":"T Pindi Sala","year":"2014","unstructured":"Pindi Sala T, Michot JM, Snanoudj R, et al. Successful outcome of a corticodependent Henoch-Sch\u00f6nlein purpura adult with rituximab. Case Rep Med. 2014;2014:619218.","journal-title":"Case Rep Med"},{"key":"1461_CR35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5455\/apr.082920130003","volume":"2","author":"M Kostik","year":"2013","unstructured":"Kostik M, Chikova I, Solovyev A, et al. The initial effectiveness of rituximab for nephrotic syndrome in severe pediatric Henoch-Schonlein glomerulonephritis. Ann Paediatr Rheumatol. 2013;2:124.","journal-title":"Ann Paediatr Rheumatol"},{"issue":"10","key":"1461_CR36","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2169\/internalmedicine.52.9325","volume":"52","author":"H Ishiguro","year":"2013","unstructured":"Ishiguro H, Hashimoto T, Akata M, et al. Rituximab treatment for adult purpura nephritis with nephrotic syndrome. Intern Med. 2013;52(10):1079\u201383.","journal-title":"Intern Med"},{"issue":"2","key":"1461_CR37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1755-6686.2013.12007.x","volume":"39","author":"A El-Husseini","year":"2013","unstructured":"El-Husseini A, Ahmed A, Sabucedo A, et al. Refractory Henoch-Schonlein purpura: atypical aetiology and management. J Ren Care. 2013;39(2):77\u201381.","journal-title":"J Ren Care"},{"issue":"6","key":"1461_CR38","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/ndt\/gfr137","volume":"26","author":"E Pillebout","year":"2011","unstructured":"Pillebout E, Rocha F, Fardet L, et al. Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report. Nephrol Dial Transplant. 2011;26(6):2044\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"1461_CR39","first-page":"327","volume":"4","author":"JP Havill","year":"2011","unstructured":"Havill JP, Levine SM, Kuperman M, et al. Falling through the cracks of vasculitis classification\u2014a report of three patients. NDT Plus. 2011;4(5):327\u201330.","journal-title":"NDT Plus"},{"issue":"3","key":"1461_CR40","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/acr.20361","volume":"63","author":"F Hauck","year":"2011","unstructured":"Hauck F, Lee-Kirsch MA, Aust D, et al. Complement C2 deficiency disarranging innate and adaptive humoral immune responses in a pediatric patient: treatment with rituximab. Arthritis Care Res. 2011;63(3):454\u20139.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1461_CR41","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpeds.2008.12.049","volume":"155","author":"KJ Donnithorne","year":"2009","unstructured":"Donnithorne KJ, Atkinson TP, Hinze CH, et al. Rituximab therapy for severe refractory chronic Henoch-Schonlein purpura. J Pediatr. 2009;155(1):136\u20139.","journal-title":"J Pediatr"},{"issue":"6","key":"1461_CR42","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1053\/j.ajkd.2008.10.039","volume":"53","author":"G Bollee","year":"2009","unstructured":"Bollee G, Noel L-H, Suarez F, et al. Pauci-immune crescentic glomerulonephritis associated with ANCA of IgA class. Am J Kidney Dis. 2009;53(6):1063\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"1461_CR43","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/archderm.142.11.1407","volume":"142","author":"L Chung","year":"2006","unstructured":"Chung L, Funke AA, Chakravarty EF, et al. Successful use of rituximab for cutaneous vasculitis. Arch Dermatol. 2006;142(11):1407\u201310.","journal-title":"Arch Dermatol"},{"key":"1461_CR44","doi-asserted-by":"crossref","unstructured":"Abdo T, Jabari A, Meharg J. Diffuse alveolar hemorrhage: a rare complication of henoch-sch\u00f6nlein purpura successfully treated with rituximab. Chest 2014;146(4).","DOI":"10.1378\/chest.1993431"},{"key":"1461_CR45","doi-asserted-by":"crossref","unstructured":"Fenoglio R, Naretto C, Basolo B et al. Rituximab therapy for IgA-vasculitis with nephritis: a case series and  review of the literature. Immunol Res. 2017;65(1):186\u2013192.","DOI":"10.1007\/s12026-016-8827-5"},{"key":"1461_CR46","unstructured":"Patel K, Kariya P, Makwana P. Henoch-Schoenle in Purpura with IgA nephropathy treated with rituximab: a case report. 2021."},{"key":"1461_CR47","doi-asserted-by":"crossref","unstructured":"Maritati, F; Fenoglio, R; Pillebout, E , et al., Brief Report: Rituximab for the Treatment of Adult\u2010Onset IgA Vasculitis (Henoch\u2010Sch\u00f6nlein). Arthritis & Rheumatology 2018;70(1):109\u2013114.","DOI":"10.1002\/art.40339"},{"issue":"2","key":"1461_CR48","first-page":"195","volume":"124","author":"R Fenoglio","year":"2020","unstructured":"Fenoglio R, Sciascia S, Naretto C, et al. Rituximab in severe immunoglobulin-A vasculitis (Henoch-Schonlein) with aggressive nephritis. Clin Exp Rheumatol. 2020;124(2):195\u2013200.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1461_CR49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-3476(85)80459-5","volume":"106","author":"SR Meadow","year":"1985","unstructured":"Meadow SR, Scott DG. Berger disease: Henoch-Sch\u00f6nlein syndrome without the rash. J Pediatr. 1985;106(1):27\u201332.","journal-title":"J Pediatr"},{"key":"1461_CR50","volume":"12","author":"Y Song","year":"2021","unstructured":"Song Y, Huang X, Yu G, et al. Pathogenesis of IgA vasculitis: an Up-To-Date review. Front Immunol. 2021;12: 771619.","journal-title":"Front Immunol"},{"key":"1461_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-019-0311-z","volume":"17","author":"M Jelusic","year":"2019","unstructured":"Jelusic M, Sestan M, Cimaz R, et al. Different histological classifications for Henoch-Sch\u00f6nlein purpura nephritis: which one should be used? Pediatr Rheumatol. 2019;17:1\u20137.","journal-title":"Pediatr Rheumatol"},{"issue":"1","key":"1461_CR52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000382134","volume":"1","author":"J Novak","year":"2015","unstructured":"Novak J, Rizk D, Takahashi K, et al. New Insights into the pathogenesis of IgA nephropathy. Kidney Dis. 2015;1(1):8\u201318.","journal-title":"Kidney Dis"},{"issue":"2","key":"1461_CR53","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MOP.0b013e3282f4308b","volume":"20","author":"JT Sanders","year":"2008","unstructured":"Sanders JT, Wyatt RJ. IgA nephropathy and Henoch-Schonlein purpura nephritis. Curr Opin Pediatr. 2008;20(2):163\u201370.","journal-title":"Curr Opin Pediatr"},{"issue":"5","key":"1461_CR54","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0272-6386(88)80028-3","volume":"12","author":"FB Waldo","year":"1988","unstructured":"Waldo FB. Is Henoch-Sch\u00f6nlein purpura the systemic form of IgA nephropathy? Am J Kidney Dis. 1988;12(5):373\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"4S","key":"1461_CR55","first-page":"S1","volume":"100","author":"K Disease","year":"2021","unstructured":"Disease K. Improving global outcomes glomerular diseases work, G, KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1\u2013276.","journal-title":"Kidney Int"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01461-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01461-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01461-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:28:47Z","timestamp":1732987727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01461-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1461"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01461-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"21 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"213"}}